Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Undervalued
The company’s latest PE is -4.34, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 270.08M shares, increasing 5.66% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.84M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.43.